Poisoning

disease
On this page

Also known as Poisonings

Summary

Poisoning (MONDO:0029000) is a disease (an umbrella term covering 59 Mondo subtypes) with 54 GWAS associations across 85 studies and 24 clinical trials. Top therapeutic interventions include chlorpheniramine, acetaminophen, and ranitidine. A subtype of disease of primarily extrinsic mechanism — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Umbrella term: 59 Mondo subtypes
  • GWAS associations: 54
  • Clinical trials: 24

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namepoisoning
Mondo IDMONDO:0029000
EFOEFO:0008546
MeSHD011041
SNOMED CT75478009
Is cancer (heuristic)no

Also known as: Poisonings

Data availability: 54 GWAS associations (85 studies).

Disease family

An umbrella term covering 59 Mondo subtypes.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › poisoning

Related subtypes (6): infectious disease, post-infectious disorder, radiation-induced disorder, iatrogenic disease, occupational disorder, disease related to transplantation

Subtypes (59): toxic oil syndrome, infantile mercury poisoning, ketamine-induced biliary dilatation, manganese poisoning, cyanide-induced parkinsonism, colchicine poisoning, methanol poisoning, ethylene glycol poisoning, paraquat poisoning, lead poisoning, mercury poisoning, acute opioid poisoning, acute tricyclic antidepressant poisoning, acute poisoning by drugs with membrane-stabilizing effect, snakebite envenomation, paracetamol poisoning, cyanide poisoning, scorpion envenomation, argyria, acute ackee fruit intoxication, cocaine intoxication, systemic monochloroacetate poisoning, water intoxication, cassavism, formaldehyde poisoning, heavy metal poisoning, abacavir toxicity, allopurinol toxicity, codeine toxicity, efavirenz toxicity, flucloxacilline toxicity, isoniazid toxicity, raltegravir toxicity, voriconazole toxicity, curariform drugs toxicity, statin toxicity, phenytoin or carbamazepine toxicity, letrozole toxicity, ricin poisoning, ivermectin toxicity, belinostat toxicity or dose selection, toxicity to dolutegravir, mycotoxicosis, ciguatera fish poisoning, lathyrism, cadmium poisoning, phenytoin toxicity, nerve agent poisoning, local anesthetic poisoning, fire ant poisoning, aflatoxicosis, black widow spider envenomation, platinum-induced ototoxicity, carbon monoxide poisoning, organophosphate poisoning, sulfur mustard poisoning, cardiac glycoside intoxication, monochloroacetic acid poisoning, chemotherapy-induced toxicity

Genetics & variants

GWAS landscape

54 GWAS associations across 85 studies. Top hits map to 28 distinct genes (as reported by GWAS).

Top associations by p-value

rsIDp-valueGeneRisk alleleOdds ratio
rs1921113131e-15PCAT19C3.45
rs1932571239e-15FOXP1C3.64
rs5504298832e-14LRRTM4 - RPL38P2T2.97
rs8674134818e-14LEP - RBM28T2.83
rs1502185959e-14NALCN-AS1T2.28
rs1466288813e-13SCARF2G3.75
rs5776826663e-13FAM136A - BRD7P6T2.98
rs2007423833e-13TMEM270G2.15
rs2015222585e-13DNAJC21G2.99
rs1455721155e-13ELAVL2 - IZUMO3A3.27
rs1480297895e-13FAM3CC3.15
rs5606887386e-13LINC02698C4.03
rs1839149801e-12LINC01060C3.9
rs5346642002e-12OLFM1 - LINC02907G3.12
rs5556667052e-12IGLV3-19 - IGLV2-18G2.98
rs5518108813e-12UBAC2G3.19
rs1871952304e-12DDX10G2.02
rs1824915774e-12SORCS1 - RNA5SP326A3.16
rs1850462415e-12LINC02577G3.68
rs7563239055e-12MTND4P33G2.7
rs9162210026e-12MPDZT2.43
rs1391257656e-12COL18A1G3.58
rs9179218447e-12DLG2T3.3
rs5345004617e-12NUS1P2 - HMGA1P6A2.59
rs1853515787e-12LINC01418G4.36
rs1908677798e-12FTH1P13 - YBX1P1G3.9
rs5534219959e-12MTX3C2.52
rs772263809e-12PRDM2 - KAZNG3.09
rs5442867849e-12SEC61G-DTC2.81
rs1869221411e-11GABRG3G2.92

Top studies (by case count)

StudyLead authorYearCasesControlsTitle
GCST90436875Zhou W201818,430381,797Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies.
GCST90436884Zhou W20186,910381,797Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies.
GCST90081050Backman JD20212,026384,627Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90085036Backman JD20212,026384,627Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90436890Zhou W20181,940381,797Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies.
GCST90081061Backman JD20211,778379,361Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90085047Backman JD20211,778379,361Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90081060Backman JD20211,659380,109Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90085046Backman JD20211,659380,109Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90081048Backman JD20211,576386,288Exome sequencing and analysis of 454,787 UK Biobank participants.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

TierVariants
Tier 1: coding0
Tier 2: splice/UTR1
Tier 3: regulatory0
Tier 4: intronic/intergenic49

MAF distribution

BucketVariants
common (>=0.05)0
low_freq (0.01-0.05)0
rare (<0.01)50
unknown0

Functional consequences

ConsequenceCount
intron_variant31
intergenic_variant15
non_coding_transcript_exon_variant2
3_prime_UTR_variant1
synonymous_variant1

Top variants

rsIDChrPosAllelesMAFConsequenceGenep-valueTier
rs1921113131941451996C>A,T0intron_variantPCAT191e-15Tier 4: intronic/intergenic
rs193257123371313204C>T0intron_variantFOXP19e-15Tier 4: intronic/intergenic
rs550429883277686311T>A,G0.001intron_variantLRRTM4 - RPL38P22e-14Tier 4: intronic/intergenic
rs8674134817128269885T>C0.001intergenic_variantLEP - RBM288e-14Tier 4: intronic/intergenic
rs15021859513100893658T>A,C0.001intron_variantNALCN-AS19e-14Tier 4: intronic/intergenic
rs1466288812220424926G>A,C,T03_prime_UTR_variantSCARF23e-13Tier 2: splice/UTR
rs577682666270335673T>A0intergenic_variantFAM136A - BRD7P63e-13Tier 4: intronic/intergenic
rs200742383773865822G>A,T0.001synonymous_variantTMEM2703e-13Tier 4: intronic/intergenic
rs201522258534944849G>A,C0.001intron_variantDNAJC215e-13Tier 4: intronic/intergenic
rs145572115924381677A>G0intergenic_variantELAVL2 - IZUMO35e-13Tier 4: intronic/intergenic
rs1480297897121364562C>T0intron_variantFAM3C5e-13Tier 4: intronic/intergenic
rs56068873811115678077C>A,T0intron_variantLINC026986e-13Tier 4: intronic/intergenic
rs1839149804188564548C>T0intron_variantLINC010601e-12Tier 4: intronic/intergenic
rs5346642009135124349G>A,C,T0.001intergenic_variantOLFM1 - LINC029072e-12Tier 4: intronic/intergenic
rs5556667052222730362G>A0.001intergenic_variantIGLV3-19 - IGLV2-182e-12Tier 4: intronic/intergenic
rs5518108811399383799G>A0.001intron_variantUBAC23e-12Tier 4: intronic/intergenic
rs18719523011108939072G>A0.001intron_variantDDX104e-12Tier 4: intronic/intergenic
rs18249157710107374836A>G0.001intergenic_variantSORCS1 - RNA5SP3264e-12Tier 4: intronic/intergenic
rs1850462417106805676G>A0.001intron_variantLINC025775e-12Tier 4: intronic/intergenic
rs7563239051484173191G>A0non_coding_transcript_exon_variantMTND4P335e-12Tier 4: intronic/intergenic
rs916221002913240981T>C0.001intron_variantMPDZ6e-12Tier 4: intronic/intergenic
rs1391257652145471173G>A0intron_variantCOL18A16e-12Tier 4: intronic/intergenic
rs9179218441185031329T>G0intron_variantDLG27e-12Tier 4: intronic/intergenic
rs5345004611323024914A>G0.002intron_variantNUS1P2 - HMGA1P67e-12Tier 4: intronic/intergenic
rs1853515781581919840G>A,C0.001intergenic_variantLINC014187e-12Tier 4: intronic/intergenic
rs1908677791465996447G>A,C0intron_variantFTH1P13 - YBX1P18e-12Tier 4: intronic/intergenic
rs553421995579991071C>A0intron_variantMTX39e-12Tier 4: intronic/intergenic
rs77226380113844057G>A,T0.001intron_variantPRDM2 - KAZN9e-12Tier 4: intronic/intergenic
rs544286784754788336C>G,T0intron_variantSEC61G-DT9e-12Tier 4: intronic/intergenic
rs1869221411527260944G>A0intron_variantGABRG31e-11Tier 4: intronic/intergenic

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated or in trials for this disease

2 approved drugs — disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

DrugStatus
AtropineApproved (phase 4)
HydroxocobalaminApproved (phase 4)

3 drugs in clinical trials for this disease (phase 2–3, investigational): efficacy not established — a trial record, not an indication.

DrugHighest phase
Magnesium Sulfate AnhydrousPhase 3
NimodipinePhase 3
LevocarnitinePhase 2

Clinical trials & evidence

Clinical trials

Clinical trials: 24.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified21
PHASE22
PHASE31

Top trials by phase / activity

NCTPhaseStatusTitle
NCT04653597PHASE3COMPLETEDNon-invasive Airway Management of Comatose Poisoned Emergency Patients
NCT06316362PHASE2COMPLETEDEfficacy of SMOF Lipid in the Management of Acute Poisoning With Carbamazepine
NCT06413589PHASE2COMPLETEDEfficacy of SMOF Lipid in the Management of Acute Poisoning With Clozapine
NCT03640143Not specifiedNOT_YET_RECRUITINGEffectiveness of Environmental Measures to Eliminate the Risks of Lead Exposure in Infant Lead Poisoning
NCT06447584Not specifiedRECRUITINGClinical Spectrum and Outcome of Poisoning in Children Admitted to the Pediatric Emergency and Intensive Care Units at Sohag University Hospital
NCT06798129Not specifiedACTIVE_NOT_RECRUITINGEffects of Extracorporeal Treatment in Patients With Acute Poisoning
NCT06926439Not specifiedACTIVE_NOT_RECRUITINGPrediction of Detoxification Effect of Fat Emulsion Based on Drug Diffusion Law
NCT07526220Not specifiedNOT_YET_RECRUITINGPrognostic Factors in Critically Ill Patients Admitted After Caustic Ingestion in France
NCT00013754Not specifiedCOMPLETEDPesticide Exposure Pathways for Farmworker Children
NCT00013767Not specifiedCOMPLETEDCommunity Based Prevention/Control Project
NCT00015600Not specifiedCOMPLETEDCommunity-Based Environmental Health Intervention
NCT00780078Not specifiedCOMPLETEDClinical Evaluation of Swallowing Disorders as a Predictor of Extubation Failure
NCT01209455Not specifiedCOMPLETEDMechanisms of N-acetylcysteine Mediated Vascular Adverse Effects
NCT02553070Not specifiedCOMPLETEDHealth Professions Students and Faculty Perceptions of Poisoning Severity
NCT03314909Not specifiedUNKNOWNInitial Hemopurification Strategy for Acute Paraquat Poisoning in Adults
NCT03894306Not specifiedWITHDRAWNUnderstanding How Medication is Stored in the Home
NCT04217070Not specifiedCOMPLETEDSuicidal Poisoning in Emergency Units
NCT04729894Not specifiedUNKNOWNEvaluating the Impact of a Safe Medication Storage Device
NCT04850014Not specifiedUNKNOWNPBPK Modelling Applied to Acetaminophen Poisoned Obese Children
NCT05098418Not specifiedUNKNOWNTrends of Acute Intoxication in Poison Control Centre
NCT05148611Not specifiedUNKNOWNApplication Registration Study of ILE in Patients With Acute Poisoning
NCT05185570Not specifiedUNKNOWNPrognosis of Elderly Patients With Acute Poisoning.
NCT05229419Not specifiedCOMPLETEDPattern of Acute Pediatric Poisoning at Assiut University Hospitals
NCT05649891Not specifiedUNKNOWNChecklists Resuscitation Emergency Department

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
CHLORPHENIRAMINE43
ACETAMINOPHEN41
RANITIDINE41